Are there published reports of lurbinectedin exposure in breastfed infants?
I don’t have any provided information indicating that there are published case reports or observational studies documenting lurbinectedin effects in breastfed infants. No such reports are included in the information available here.
What’s known clinically about lurbinectedin in breastfeeding?
The key practical issue is that lurbinectedin is an anticancer drug, and many cancer therapies carry breastfeeding concerns because of potential drug transfer into breast milk and possible harm to an infant. However, without specific data or a cited report, I can’t confirm whether infant exposure has been measured or whether any harm has been documented.
Is there guidance on whether to breastfeed during lurbinectedin treatment?
No breastfeeding guidance text (for example, “avoid breastfeeding” vs “pause breastfeeding for X days”) is included in the information available here, so I can’t cite an authoritative recommendation.
If you’re deciding now, what do clinicians typically rely on?
When there’s no documented infant-report evidence, clinicians usually base decisions on:
- Whether the medication is expected to enter breast milk.
- The potential toxicity profile in infants.
- The availability of alternative feeding strategies and the urgency of cancer treatment.
Where to look for confirmed case reports
If you want to verify whether any infant-exposure reports exist, the fastest path is to search:
- Pharmacovigilance databases (e.g., case-report listings)
- Drug label safety sections
- Medical literature terms like “lurbinectedin” plus “breastfeeding,” “lactation,” or “infant”
If you share the source document or label text you’re using (or a link), I can help interpret whether it mentions any breastfed-infant reports and what it recommends.
Sources: none (no provided information contained reports or label text about lurbinectedin and breastfed infants).